Navigation Links
Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
Date:11/4/2008

NEW BRUNSWICK, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) today announced that the Company will be presenting at the 10th Annual Rodman & Renshaw Healthcare Conference, which is being held at the New York Palace Hotel from November 10-12, 2008. Sascha P. Fedyszyn, Vice President, Corporate Development of Senesco, will deliver the Company's corporate presentation on Tuesday, November 11th, at 5:20 PM ET.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. The firm also provides research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the private investment in public equity (PIPE) and registered direct placements (RD) transaction markets.

The conference will feature innovative growth companies and investors interested in such companies and will focus on firms within the Life Science, Energy and Natural Resources sectors, as well as firms based in promising Emerging Markets. Last year's conference, which focused solely on Life Science firms, attracted more than 2,500 investors and industry attendees and included presentations by more than 350 companies.

About Senesco Technologies, Inc.

Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contact: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5600

(732) 296-8400


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senesco Expands on Preclinical Multiple Myeloma Findings
2. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
3. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
4. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
7. Advanced technologies aim to transform the coaching of top athletes
8. Global Med Technologies(R) Extends Its Worldwide Outreach
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
11. Neurobiological Technologies Reports Going Concern Qualification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, ... solutions for the food and beverage industry offers Citri-Fi®, a natural citrus fiber, ... the purchasing decision process. As a result, labels need to deliver simple, transparent ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand ... Integration company, announced today that its iClinic V12.2 solution has achieved approval from ... NCQA recently introduced PCMH 2017 standards which emphasize team-based care with a significant ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i ... 2017 Best in KLAS category winner, has named Daniel P. Bullington as chief ... enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel is ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
(Date:5/4/2017)... WAYNE, Pa. , May 4, 2017 /PRNewswire/ ... made from thermoplastics and other highly-engineered materials, is ... Microextrusion tubing has been developed in recent ... neurovascular interventional therapies and surgical applications. More expensive ... used to produce microextrusion tubing due to their ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
Breaking Medicine Technology: